The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...
Crohn’s disease and ulcerative colitis (UC) are both types of inflammatory bowel disease (IBD) that share similar symptoms but differ in their affected areas, disease progression, and ...